OSE — Ose Immunotherapeutics SA Income Statement
0.000.00%
Last trade - 00:00- €124.89m
- €154.27m
- €83.44m
- 66
- 88
- 39
- 75
Annual income statement for Ose Immunotherapeutics SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 10.4 | 26.3 | 18.3 | 2.23 | 83.4 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 29.4 | 42.9 | 36.8 | 25.2 | 39.7 |
| Operating Profit | -19 | -16.6 | -18.5 | -23 | 43.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -19.2 | -17.2 | -18 | -23.2 | 39.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.6 | -16.8 | -17.8 | -23 | 37.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.6 | -16.8 | -17.8 | -23 | 37.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.6 | -16.9 | -17.8 | -23 | 37.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.06 | -0.916 | -0.952 | -1.19 | 1.48 |
| Dividends per Share |